- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing | ||
| Fr | Big Pharma's 'Brexit' draws call for anticompetition probe from advocacy groups: report | ||
| Fr | 4 reasons why life sciences still fail women at the top, despite a female-majority workforce: report | ||
| Fr | Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate | ||
| Fr | With FDA approval, Jazz Pharma and Roche's combo sets new bar in first-line small cell lung cancer | ||
| Fr | GSK overturns UK watchdog's most serious sanction in COVID press release row | ||
| Do | Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher's NC production facility | ||
| Do | Amgen charts late-stage win for Repatha in broad cardiovascular risk population | ||
| Do | Acadia, e-therapeutics unveil rebrands to better represent their drugmaking missions | ||
| Do | Vanda and the FDA make nice, agreeing to squash several disputes following appeals court win | ||
| Do | AbbVie, BeOne end BTK blood cancer drug patent fight | ||
| Do | Ansa snares $54.4M in series B financing to boost its DNA synthesis platform | ||
| Do | Regulatory tracker: J&J's Tremfya picks up 2 pediatric approvals from FDA | ||
| Mi | Halozyme buys subcutaneous drug delivery peer Elektrofi for up to $900M | ||
| Mi | Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat | ||
| Mi | FDA snubs Cyprium-Sentynl drug for rare pediatric disease due to manufacturing issues | ||
| Mi | FDA avoids the worst amid government shutdown, but new applications put on hold | ||
| Mi | AbbVie charts next leg of US investment journey with $70M expansion in Mass. | ||
| Mi | Bayer consolidates global consumer health marketing, naming IPG as sole creative and media partner | ||
| Mi | Sanofi's German, French premises hit by EU probe amid vaccines market abuse concerns | ||
| Di | Indivior to discontinue Opvee marketing after New York settlement | ||
| Di | Novartis earns FDA's ire for 'misleading' romantic storyline of Fabhalta TV ad | ||
| Di | Korea's Boryung looks to stir up new value in Sanofi's legacy chemo Taxotere with $205M rights buy | ||
| Di | Pfizer plans to offer price concessions in Trump's 'most favored nation' push: reports | ||
| Di | AnaptysBio plans to split biotech and Jemperli royalties into separate businesses |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .